Scientists Find Way to Reduce Inflammation from Vaccines | Drug Discovery And Development
SEP 13, 2020 10:50 AM PDT

Scientists Find Way to Reduce Inflammation from Vaccines

WRITTEN BY: Annie Lennon

Researchers from the University of Chicago have found a new way to reduce vaccine-related inflammation from adjuvants, a key ingredient in modern vaccines that helps create an immuno-response that protects against various diseases. 

While adjuvants are useful for activating inflammatory cytokines that are then able to protect against various diseases, some cause an excessive inflammatory response in the body and are thus difficult to implement in vaccine development. As such, the researchers behind the present study wanted to find a way to limit the possibility of inflammation while still guaranteeing the desired immune response. 

After some searching, they came across a peptide known as SN50, which, as tests demonstrated, had the potential to disrupt pathways in cells that typically lead to excessive inflammation. In particular, this molecule seemed to interrupt a protein called NF-kB, known to produce inflammatory cytokines. Adding the molecule to a range of drugs, they found it was able to reduce inflammation and increase antibodies against various diseases in mouse models. 

In mice with dengue, for example, they found that the molecule helped the body produce more antibodies to neutralize the virus. Meanwhile, in those with HIV, they found it also helped produce more antibodies that targeted hard-to-reach areas of the virus. It was also able to enhance a pre-existing flu vaccine's efficacy. 

The next step for the researchers is to find whether a molecule smaller than a peptide is able to produce the same results. They also want to investigate how such a molecule could aid immunotherapy treatments for cancer and other health conditions. In particular, they say that their research has many implications for how vaccines may be designed in the next 5- 10 years, and could one day aid in the development of vaccines against SARS-CoV-2, especially if it becomes a seasonal threat. 

 

Sources: Neuroscience NewsScience Advances

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
AUG 06, 2020
Drug Discovery & Development
How Medieval Medicine Can Conquer Modern Day Infections?
AUG 06, 2020
How Medieval Medicine Can Conquer Modern Day Infections?
One of our current global threats is antibiotic resistance.     As more biofilm-associated infections are ...
AUG 24, 2020
Drug Discovery & Development
FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19
AUG 24, 2020
FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19
The US Food and Drug Agency (FDA) has given emergency approval for expanded use of antibody-rich blood plasma to help th ...
SEP 15, 2020
Drug Discovery & Development
Turmeric Better than Placebo for Osteoarthritis Pain
SEP 15, 2020
Turmeric Better than Placebo for Osteoarthritis Pain
Researchers from the University of Tasmania in Australia have found that an extract from turmeric is more effective than ...
SEP 16, 2020
Drug Discovery & Development
Generic Cholesterol-Lowering Drugs Save Money
SEP 16, 2020
Generic Cholesterol-Lowering Drugs Save Money
Generic Cholesterol Drugs Are Saving Money Between 2014 to 2018, there has been a switch from brand name to generic chol ...
OCT 15, 2020
Cannabis Sciences
Can Cannabis Treat Traumatic Brain Injury?
OCT 15, 2020
Can Cannabis Treat Traumatic Brain Injury?
Traumatic brain injury (TBI) happens when the head is violently hit by an object or when an object pierces the skull and ...
OCT 20, 2020
Cannabis Sciences
Should Cannabis Doses Be Standardized?
OCT 20, 2020
Should Cannabis Doses Be Standardized?
Should cannabis and its compounds such as tetrahydrocannabinol (THC), the psychoactive compound in cannabis, come in sta ...
Loading Comments...